CASE DESCRIPTION {#s1}
================

A 56-year-old man without relevant medical history reported an episode of malaise, weakness, night sweats, and unintended weight loss followed by right upper quadrant abdominal pain worsened by inspiration. Laboratory testing ([Table 1](#T1){ref-type="table"}) revealed mild anemia, an elevated C-reactive protein of 55 mg/L, slightly elevated alkaline phosphatase, and negative tumor markers. Abdominal ultrasound and computed tomography (CT) identified an ill-defined mass of 9x5.5x6cm in the periphery of liver segments V/VI/VIII with one subcapsular, peripheral coarse calcification and inhomogeneous contrast enhancement in CT. As a fibrolamellar hepatocellular carcinoma was suspected, a positron emission tomography (PET--CT) was added for staging ([Figure 1](#F1){ref-type="fig"}), which revealed high focal fluorodeoxyglucose (FDG) uptake of the hepatic mass without other lesions. A liver biopsy showed no malignancy, but periportal and portal fibrosis.

###### 

Laboratory Results

  Parameter                                      Measurement \[Reference Range\]
  ---------------------------------------------- ---------------------------------
  Hemoglobin                                     125 g/L \[134--170 g/L\]
  White blood count                              9.07 G/L \[3.0--9.6 G/L\]
  Platelets                                      270 G/L \[143--400 G/L\]
  AST                                            21 U/L \[\<50 U/L\]
  ALT                                            21 U/L \[\<50 U/L\]
  gGT                                            58 U/L \[\<60 U/L\]
  AP                                             146 U/L \[40--129 U/L\]
  Bilirubine                                     5 µmol/L \[\<21 µmol/L\]
  CRP                                            55 mg/L \[\<5 mg/L\]
  AFP                                            3.1 µg/L \[\<13.1 µg/L\]
  CA 19-9                                        7.9 kU/L \[\<37 kU/L\]
  CEA                                            \<1.0 µg/L \[\<5.0 µg/L\]
  *Brucella* agglutination assay                 Positive \[negative\] (11/15)
                                                 Positive \[negative\] (01/16)
                                                 Positive \[negative\] (02/16)
  *Brucella* IgM^a^                              \<5 U/L \[\<15 U/L\] (11/15)
                                                 \<5 U/L \[\<15 U/L\] (01/16)
                                                 5.54 U/L \[\<15 U/L\] (02/16)
  *Brucella* IgG^b^                              207.8 U/L \[\<20 U/L\] (11/15)
                                                 163.0 U/L \[\<20 U/L\] (01/16)
                                                 127.6 U/L \[\<20 U/L\] (02/16)
  *Brucella* IgA^c^                              \>100 U/L \[\<10 U/L\] (11/15)
                                                 89.7 U/L \[\<10 U/L\] (01/16)
                                                 \>100 U/L \[\<10 U/L\] (02/16)
  *Brucella* spp.--speficic PCR (liver biopsy)   Negative \[negative\] (11/15)
                                                 Negative \[negative\] (07/16)
                                                 Positive \[negative\] (05/17)

Laboratory results at time of presentation (11/15), if other not specified.

Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; CA 19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CRP, C-reative protein; gGT, gamma-glutamyl transpeptidase; PCR, polymerase chain reaction.

^a^Virion/serion SERION enzyme-linked immunosorbent assay (ELISA) *classic* Brucella IgM.

^b^Virion/serion SERION ELISA *classic* Brucella IgG.

^c^Virion/serion SERION ELISA *classic* Brucella IgA.

![Computed tomography (CT), positron emission tomography (PET)--CT, and magnetic resonance imaging (MRI) of the liver mass. A, Contrast-enhanced CT at initial diagnosis (08/15) with a coarse calcification and adjacent hyperenhancement of the liver parenchyma in segments V/VI/VIII. B, FDG-PET-CT (09/15) shows corresponding FDG uptake of the hepatic lesion (SUVmax, standardized uptake value, 16.8). C, Contrast-enhanced MRI (10/15) with a T2-weighted fat-saturated image (C.1), contrast-enhanced images in the portal-venous (C.2), and hepatobiliary phase (C.3) showing the hypointense calcification (arrow). The adjacent area is hyperintense on T2 with increased contrast enhancement in the portal-venous phase and markedly decreased contrast enhancement in the hepatobiliary phase. D, Follow-up MRI (04/16) with contrast-enhanced image showing a subcapsular, septated hepatic abscess.](ofy05201){#F1}

Further workup included magnetic resonance imaging (MRI) with hepatobiliary contrast agent (Gd-EOB-DTPA), which confirmed an ill-defined mass in liver segments V/VI/VIII. Adjacent to the calcification, an ill-defined area with T2 fat-sat hyperintense signal and arterial hyperenhancement was present. In the center of this area, portal-venous and hepatobiliary contrast enhancement was decreased, representing the area of chronic inflammation. A fluid collection resembling a hepatic abscess was not seen. A second biopsy confirmed chronic portal and lobular inflammation with non-necrotizing microgranulomas, respectively ([Figure 2](#F2){ref-type="fig"}). Histology triggered serologic testing for *Bartonella* spp., *Brucella* spp., and *Coxiella burnetii*. Agglutination test for brucellosis was reactive, and enzyme-linked immunosorbent assay (ELISA) confirmed elevated titers of *Brucella* IgG and IgA. However, *Brucella* spp.--specific polymerase chain reaction (PCR) of paraffin-embedded liver tissue tested negative. Serology for *Coxiella burnetii* and *B. henselae* tested negative. Serological, radiological, and histological findings together with the risk factor, consumption of unpasteurized dairy products, resulted in the diagnosis of hepatic brucelloma. Treatment with doxycycline 100 mg bis in die (BID) and rifampin 300 mg ter in die (TID) was initiated. After initial improvement, abdominal pain and persistent elevation of inflammatory markers reoccurred. Abdominal MRI 5 months after treatment initiation revealed a new septated, subcapsular hepatic fluid collection suspicious of an abscess, prompting diagnostic and therapeutic puncture. Histopathology showed persistence of chronic granulomatous hepatitis. *Brucella* spp.--specific PCR and culture were negative. At this time, trimethoprim/sulfamethoxazole 160/800 mg BID was added to the antibiotic therapy. Due to subsequent clinical and laboratory improvement (C-reactive protein 10 mg/L, erythrocyte sedimentation rate 16 mm/h), antibiotics were stopped after 13 months of treatment. After 12 weeks, a clinically, laboratory-, and imaging-verified relapse occurred. Doxycycline and rifampin were resumed, and the decision for surgical removal was taken. Perioperatively, gentamicin was added to reduce bacterial load and discontinued 1 week after partial hemihepatectomy. The postoperative course was uncomplicated, with rapid clinical and laboratory improvement. *Brucella* spp.--specific PCR of the resected liver tissue was positive; culture remained negative. A follow up CT 3 months postoperation confirmed complete resection, and antibiotic therapy was stopped.

![Liver biopsy (11/15) showing portal and peripheral inflammation and a microgranuloma. ^a^Portal inflammation. ^b^Peripheral inflammation. ^c^Magnification of a microgranuloma.](ofy05202){#F2}

DISCUSSION {#s2}
==========

Brucellosis is a frequent zoonosis caused by gram-negative facultative intracellular coccobacilli *Brucella* spp. Humans constitute secondary hosts. Transmission results either from ingestion of unpasteurized dairy products or direct contact with infected animals. After an incubation period of 2 to 4 weeks, an unspecific syndrome of fever, weight loss, malaise, myalgia, and arthralgia presents \[[@CIT0001]\]. Subclinical presentations are possible. No or insufficient treatment can lead to chronic brucellosis \[[@CIT0001]\], of which hepatic brucelloma is an infrequent complication, with a reported incidence of 1.7% \[[@CIT0002]\]. Symptoms of hepatic brucelloma are unspecific, including fever, chills, sweating, weakness, and upper abdominal pain. Laboratory tests frequently show signs of inflammation and occasionally elevations of gamma-glutamyl transpeptidase and alkaline phosphatase \[[@CIT0002]\]. Serological tests, mostly agglutination assays, can be used for diagnosis. Cultural approaches are characterized by a low sensitivity (29.4%) \[[@CIT0003]\], whereas PCR of biopsy samples is reported to be highly sensitive (97.1%) \[[@CIT0003]\]. Here, *Brucella* spp. PCR of percutaneous liver biopsies was negative, likely reflecting reduced sensitivity with the use of paraffin-embedded tissue and prior antibiotic therapy. *Brucella* spp. PCR was only positive in operatively obtained samples.

Hepatic brucelloma presents as a hypodense lesion with perifocal calcium deposits and contrast enhancement on CT scans \[[@CIT0004]\]. In the only published case describing PET-CT findings, high focal FDG uptake was reported \[[@CIT0001]\]. Liver biopsies frequently display granulomatous, portal, and peripheral inflammation \[[@CIT0005], [@CIT0006]\].

Treatment recommendations for hepatic brucelloma are scarce. In a recent review, combination therapy with doxycycline and rifampin was most often used, with a wide variability of treatment duration \[[@CIT0001]\]. Occasionally, puncture or surgical resection was necessary for cure \[[@CIT0007]\]. A decay in antibody titers during treatment is described, but no cutoff corresponding to treatment success has been established \[[@CIT0008]\].

CONCLUSIONS {#s3}
===========

Even advanced, noninvasive imaging methods cannot distinguish between hepatic malignancy and brucelloma. The optimal treatment for hepatic brucelloma is unknown, but prolonged antibiotic treatment combined with surgery can be necessary.

We thank the patient for his willingness to have his case published.
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